Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.315 USD | -1.13% | -6.07% | -1.87% |
04-24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
03-25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.87% | 336M | |
+32.99% | 698B | |
+26.51% | 568B | |
-4.39% | 358B | |
+19.19% | 328B | |
+3.87% | 283B | |
+16.42% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.49% | 165B |
- Stock Market
- Equities
- PGEN Stock
- News Precigen, Inc.
- Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe